Literature DB >> 20012497

Stable modifications to the expression of neurohormones in the rat hypothalamus in a model of post-traumatic stress disorder.

V I Mironova1, E A Rybnikova.   

Abstract

We report studies of the neuroendocrine mechanisms of development of an anxiety state in rats using the "stress-restress" experimental model of post-traumatic stress disorder. Immunocytochemical methods demonstrated significant increases in corticoliberin expression in both the parvo- and magnocellular parts of the paraventricular nucleus persisting to 10 days after presentation of the animals with repeated stress. Decreases in vasopressin expression were seen in the paraventricular nucleus of the animals on the first day after repeated stress. Vasopressin contents in the parvocellular part of the nucleus in animals of the experimental group were no different at 10 days from those in animals of the control group, while levels in the magnocellular part were increased. These data provide evidence for the involvement of the hypothalamic component of the vasopressinergic system (along with the corticoliberinergic system) in the pathogenetic mechanisms of the analog of post-traumatic stress disorder generated in this model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20012497     DOI: 10.1007/s11055-009-9216-5

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  18 in total

Review 1.  Animal models of anxiety disorders.

Authors:  Joachim D K Uys; Dan J Stein; Willie M U Daniels; Brian H Harvey
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 2.  Physiology and pharmacology of corticotropin-releasing factor.

Authors:  M J Owens; C B Nemeroff
Journal:  Pharmacol Rev       Date:  1991-12       Impact factor: 25.468

Review 3.  Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation.

Authors:  G Aguilera; C Rabadan-Diehl
Journal:  Regul Pept       Date:  2000-12-22

Review 4.  Corticotropin-releasing hormone modulators and depression.

Authors:  Florian Holsboer
Journal:  Curr Opin Investig Drugs       Date:  2003-01

5.  Lower cortisol levels in depressed patients with comorbid post-traumatic stress disorder.

Authors:  M A Oquendo; G Echavarria; H C Galfalvy; M F Grunebaum; A Burke; A Barrera; T B Cooper; K M Malone; J John Mann
Journal:  Neuropsychopharmacology       Date:  2002-08-19       Impact factor: 7.853

Review 6.  Corticotropin-releasing hormone in depression and post-traumatic stress disorder.

Authors:  J W Kasckow; D Baker; T D Geracioti
Journal:  Peptides       Date:  2001-05       Impact factor: 3.750

7.  Enhanced cortisol suppression in response to dexamethasone administration in traumatized veterans with and without posttraumatic stress disorder.

Authors:  C S de Kloet; E Vermetten; C J Heijnen; E Geuze; E G W M Lentjes; H G M Westenberg
Journal:  Psychoneuroendocrinology       Date:  2007-02-12       Impact factor: 4.905

Review 8.  Vasopressin as a target for antidepressant development: an assessment of the available evidence.

Authors:  Lucinda V Scott; Timothy G Dinan
Journal:  J Affect Disord       Date:  2002-11       Impact factor: 4.839

9.  Endocrine, cognitive and hippocampal/cortical 5HT 1A/2A receptor changes evoked by a time-dependent sensitisation (TDS) stress model in rats.

Authors:  Brian H Harvey; Carla Naciti; Linda Brand; Dan J Stein
Journal:  Brain Res       Date:  2003-09-05       Impact factor: 3.252

10.  Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder.

Authors:  C S de Kloet; E Vermetten; E Geuze; E G W M Lentjes; C J Heijnen; G K Stalla; H G M Westenberg
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

View more
  1 in total

1.  Pathogenetic Role of the Stress-induced Release of Glucocorticoid Hormones in the Development of Post-traumatic Stress Disorder: An Experimental Study.

Authors:  M Y Zenko; K A Baranova; E A Rybnikova
Journal:  Dokl Biol Sci       Date:  2018-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.